Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction

Urology. 2006 Oct;68(4):689-96. doi: 10.1016/j.urology.2006.05.009.

Authors

Ridwan Shabsigh¹, Allen D Seftel, Raymond C Rosen, Hartmut Porst, Sanjeev Ahuja, Michael C Deeley, Carmen S Garcia, François Giuliano

Affiliation

¹ Department of Urology, Columbia-Presbyterian Medical Center, New York, New York 10032, USA.

PMID: 17070333
DOI: 10.1016/j.urology.2006.05.009

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
Carbolines / therapeutic use
Cyclic Nucleotide Phosphodiesterases, Type 5
Erectile Dysfunction / drug therapy*
Humans
Imidazoles / therapeutic use
Male
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use
Purines
Sildenafil Citrate
Sulfones / therapeutic use
Tadalafil
Time Factors
Treatment Outcome
Triazines / therapeutic use
Vardenafil Dihydrochloride

Substances

Carbolines
Imidazoles
Phosphodiesterase Inhibitors
Piperazines
Purines
Sulfones
Triazines
Vardenafil Dihydrochloride
Tadalafil
Sildenafil Citrate
3',5'-Cyclic-GMP Phosphodiesterases
Cyclic Nucleotide Phosphodiesterases, Type 5
PDE5A protein, human